David S Mathai

David S Mathai
Johns Hopkins Medicine | JHUSOM · Department of Psychiatry and Behavioral Sciences

MD

About

21
Publications
2,154
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
54
Citations
Introduction
David Mathai, MD is interested in interdisciplinary approaches to psychopharmacology research and has studied behavioral models of addiction and cognitive impairment, neuropsychiatric effects of cannabis, and antidepressant properties of ketamine. His current postdoctoral work focuses on applications of psychedelic medicine within phenomenologically- and psychologically-oriented frameworks.
Additional affiliations
August 2012 - July 2013
Kaplan Test Prep
Position
  • Instructor
Description
  • Taught physics, biology, chemistry, and verbal reasoning for MCAT preparation course
August 2010 - December 2012
Texas A&M University
Position
  • Department Tutor
Description
  • Tutored university students in chemistry, microbiology, genetics, and biochemistry
January 2009 - May 2009
University of North Texas
Position
  • Research Assistant
Description
  • Tutored university students for Dr. Sushama Dandekar as supplement to organic chemistry course
Education
July 2013 - May 2017
Baylor College of Medicine
Field of study
  • Medicine
August 2009 - December 2012
Texas A&M University
Field of study
  • Biochemistry, Genetics, English

Publications

Publications (21)
Article
Full-text available
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans. The α2A-adrenoceptor (AR) agonist guanfacine improves working memory performance in humans. The authors aimed to determine the effects of short-term (6 days) treatment with g...
Article
Full-text available
Background The relationship between adolescent cannabis use and susceptibility to persistent cognitive impairments is poorly understood. Aims We examined the effects of repeated exposure to Δ-9-tetrahydrocannabinol (THC) on reinforcement-related learning and performance of spatial working memory (WM) tasks of varying difficulty in adolescent monke...
Article
Full-text available
Objective: The relationship between ketamine's hallucinogenic- and dissociative-type effects and antidepressant mechanism of action is poorly understood. This paper reviewed the correlation between subjective effects defined by various psychometric scales and observed clinical outcomes in the treatment of patients with Major Depressive Disorder (M...
Article
Full-text available
Objectives: Investigation into parental decision-making processes involving ketamine is of high priority, given the necessary role of parents in consenting to treatment. In this study, we examined parental attitudes toward the emerging use of ketamine in adolescent mood disorders and suicidality. Methods: Two hundred eighty-three English-speaking p...
Article
Full-text available
Ketamine is a dissociative drug that has been used medically since the 1970s primarily as an anesthetic agent but also for various psychiatric applications. Anecdotal reports and clinical research suggest substantial potential for ketamine as a treatment in conjunction with psychological interventions. Here, we review historical and modern approach...
Article
Full-text available
Background: Given increasing community-based and off-label use of ketamine for psychiatric indications, we examined current informed consent processes from a convenience sample of outpatient ketamine clinics to identify areas of congruence with current evidence and opportunities for growth. Methods: Using a rubric developed from existing practic...
Article
Full-text available
Brief response letter published to The British Journal of Psychiatry on the topic of subjective "highs" associated with esketamine and other medical hallucinogens.
Article
Background The COVID-19 pandemic has led to increased stress, anxiety, and depression in children. A six-session, parent-led, transdiagnostic, cognitive-behavioral teletherapy program was adapted from an established protocol to help youth aged between 5 and 13 years manage emotional problems during the pandemic. Methods One-hundred twenty-nine par...
Article
Given that children and adolescents are at critical periods of development, they may be particularly vulnerable to the effects of the COVID-19 pandemic. Using a descriptive phenomenological approach, 71 parents’ observations of their child’s mental health difficulties were explored. Parents sought out treatment because their children were experienc...
Article
Introduction Obsessive-compulsive disorder (OCD) is a common psychiatric disorder that can be chronic and debilitating if not properly treated. Current first-line treatments for OCD include cognitive-behavioral therapy with exposure and response prevention (CBT) and serotonin uptake inhibitor medications (SRI); however, these therapies are not effe...
Article
Background and objectives: No medication has Food and Drug Administration approval for cannabis use disorder (CUD), and most medication development focuses on the withdrawal syndrome. We evaluated the effects of short-term treatment using the α-2A-adrenergic receptor agonist, guanfacine, on withdrawal symptoms in volunteers with CUD and a history...
Article
Full-text available
Synthetic cannabinoids (SCs) have become a major drug of abuse associated with severe hospital presentations. There have been a variety of legislative efforts to regulate these drugs: The authors focus on trends in SC-related hospitalizations at Ben Taub General Hospital before and after a ban enacted by the city of Houston. Data from all consults...
Poster
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC) impairs working memory performance in humans. The α2A-adrenoceptor (α2A-AR) agonist guanfacine improves working memory performance in humans. We employed a double-blind, placebo-controlled crossover study to determine the effects of short-term (6-days) treatment with guanfacine...
Article
Background/objectives: Certain medical consequences seem unique to synthetic cannabinoid (SC) and not cannabis use. We report the case of an adolescent, whose drug expectancies appear to minimize the severity of SC-related adverse events. Methods/results: An 18-year-old male presented with altered mental status and seizure, complicated by respir...
Chapter
This chapter reviews the epidemiology of childhood maltreatment and Post-traumatic Stress Disorder (PTSD), as well as the diagnosis, neurophysiology, genetics, and pharmacological and nonpharmacological treatment of PTSD. The problem of childhood maltreatment-related trauma leading to PTSD is receiving growing attention from epidemiologists, psychi...
Poster
Full-text available
The earliest reports of synthetic cannabinoid (SC) trafficking in the US date back to December 2008, and since then, cannabis homologs have become a major drug of abuse. These products are chemically distinct from cannabis in a number of ways, and growing acknowledgement of their harmful effects has led to efforts across all levels of government to...
Poster
Alzheimer’s disease (AD) is the most common form of dementia, a neurological condition characterized by cognitive impairment and the inability to perform daily tasks. Neuritic protein aggregates in the brain, known as plaques, are a hallmark of AD pathology. These plaques are deposits of the amyloid-beta (A-Beta) peptide, which is derived from a la...
Poster
The hippocampus is one of the earliest brain regions affected in Alzheimer’s Disease (AD). In fact, neuropsychological assessments dependent on the region, such as delayed paragraph recall, are the most reliable in effective diagnosis of the disease. However, by the time individuals are impaired on these widely used assessments, many already have l...

Network

Cited By

Projects

Projects (2)
Project
Research involving psychiatric uses of ketamine/esketamine
Archived project
Investigating role of cannabis/cannabinoids in psychiatry